Your browser doesn't support javascript.
loading
Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop.
Osoegawa, Kazutoyo; Vayntrub, Tamara A; Wenda, Sabine; De Santis, Dianne; Barsakis, Konstantinos; Ivanova, Milena; Hsu, Susan; Barone, Jonathan; Holdsworth, Rhonda; Diviney, Mary; Askar, Medhat; Willis, Amanda; Railton, Dawn; Laflin, Sophie; Gendzekhadze, Ketevan; Oki, Arisa; Sacchi, Nicoletta; Mazzocco, Michela; Andreani, Marco; Ameen, Reem; Stavropoulos-Giokas, Catherine; Dinou, Amalia; Torres, Margareth; Dos Santos Francisco, Rodrigo; Serra-Pages, Carles; Goodridge, Damian; Balladares, Sandra; Bettinotti, Maria P; Iglehart, Brian; Kashi, Zahra; Martin, Russell; Saw, Chee Loong; Ragoussis, Jiannis; Downing, Jonathan; Navarrete, Cristina; Chong, Winnie; Saito, Katsuyuki; Petrek, Martin; Tokic, Stana; Padros, Karin; Beatriz Rodriguez, Ma; Zakharova, Viktoria; Shragina, Olga; Marino, Susana R; Brown, Nicholas K; Shiina, Takashi; Suzuki, Shingo; Spierings, Eric; Zhang, Qiuheng; Yin, Yuxin.
Afiliación
  • Osoegawa K; Histocompatibility, Immunogenetics, and Disease Profiling Laboratory, Stanford Blood Center, Palo Alto, CA, USA. Electronic address: kazutoyo@stanford.edu.
  • Vayntrub TA; Histocompatibility, Immunogenetics, and Disease Profiling Laboratory, Stanford Blood Center, Palo Alto, CA, USA.
  • Wenda S; Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
  • De Santis D; PathWest, Fiona Stanley Hospital, Murdoch, WA, Australia.
  • Barsakis K; Histocompatibility, Immunogenetics, and Disease Profiling Laboratory, Stanford Blood Center, Palo Alto, CA, USA; University of Crete, Biology Department, Heraklion, Greece; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Ivanova M; Alexandrovska Hospital, Sofia, Bulgaria.
  • Hsu S; Histocompatibility/Molecular Genetics, American Red Cross, Philadelphia, PA, USA.
  • Barone J; Histocompatibility/Molecular Genetics, American Red Cross, Philadelphia, PA, USA.
  • Holdsworth R; Australian Red Cross Blood Services, Melbourne, Australia.
  • Diviney M; Australian Red Cross Blood Services, Melbourne, Australia.
  • Askar M; Baylor University Medical Center, Dallas, TX, USA.
  • Willis A; Baylor University Medical Center, Dallas, TX, USA.
  • Railton D; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Laflin S; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Gendzekhadze K; City of Hope National Medical Center, Duarte, CA, USA.
  • Oki A; City of Hope National Medical Center, Duarte, CA, USA.
  • Sacchi N; Ente Ospedaliero Ospedali Galliera, Genova, Italy.
  • Mazzocco M; Ente Ospedaliero Ospedali Galliera, Genova, Italy.
  • Andreani M; Fondazione I.M.E. Istituto Mediterraneo Di Ematologia, Rome, Italy.
  • Ameen R; Health Sciences Center, Kuwait University, Jabriya, Kuwait.
  • Stavropoulos-Giokas C; Hellenic Cord Blood Bank, Athens, Greece.
  • Dinou A; Hellenic Cord Blood Bank, Athens, Greece.
  • Torres M; Hospital Albert Einstein, Sao Paulo, Brazil.
  • Dos Santos Francisco R; Hospital Albert Einstein, Sao Paulo, Brazil.
  • Serra-Pages C; Centro de Diagonóstico Biomédico, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Goodridge D; Illumina, Inc., San Diego, CA, USA.
  • Balladares S; Illumina, Inc., San Diego, CA, USA.
  • Bettinotti MP; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Iglehart B; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Kashi Z; Kashi Clinical Laboratories, Inc., Portland, OR, USA.
  • Martin R; Kashi Clinical Laboratories, Inc., Portland, OR, USA.
  • Saw CL; McGill University Health Centre, Montreal, QC, Canada.
  • Ragoussis J; McGill University Health Centre, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Downing J; New Zealand Blood Service, Epsom, Auckland, New Zealand.
  • Navarrete C; National H&I Service Development Laboratory NHS Blood and Transplant, London, UK.
  • Chong W; National H&I Service Development Laboratory NHS Blood and Transplant, London, UK.
  • Saito K; One Lambda, Thermo Fisher Scientific, Canoga Park, CA, USA.
  • Petrek M; Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
  • Tokic S; Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
  • Padros K; Primer Centro Argentino de Immunogenetica (PRICAI), Fundación Favaloro, CABA, Argentina.
  • Beatriz Rodriguez M; Primer Centro Argentino de Immunogenetica (PRICAI), Fundación Favaloro, CABA, Argentina.
  • Zakharova V; Rogachev Federal Research Centre of Pediatric Hematology,Oncology and Immunology, Moscow, Russian Federation.
  • Shragina O; Rogachev Federal Research Centre of Pediatric Hematology,Oncology and Immunology, Moscow, Russian Federation.
  • Marino SR; The University of Chicago Medicine, Chicago, IL, USA.
  • Brown NK; The University of Chicago Medicine, Chicago, IL, USA.
  • Shiina T; Tokai University School of Medicine, Kanagawa, Japan.
  • Suzuki S; Tokai University School of Medicine, Kanagawa, Japan.
  • Spierings E; University Medical Center Utrecht, Netherlands.
  • Zhang Q; University of California, Los Angeles, Immunogenetics Center, Los Angeles, CA, USA.
  • Yin Y; University of California, Los Angeles, Immunogenetics Center, Los Angeles, CA, USA.
Hum Immunol ; 80(4): 228-236, 2019 Apr.
Article en En | MEDLINE | ID: mdl-30738112
ABSTRACT
The 17th International HLA and Immunogenetics Workshop (IHIW) organizers conducted a Pilot Study (PS) in which 13 laboratories (15 groups) participated to assess the performance of the various sequencing library preparation protocols, NGS platforms and software in use prior to the workshop. The organizers sent 50 cell lines to each of the 15 groups, scored the 15 independently generated sets of NGS HLA genotyping data, and generated "consensus" HLA genotypes for each of the 50 cell lines. Proficiency Testing (PT) was subsequently organized using four sets of 24 cell lines, selected from 48 of 50 PS cell lines, to validate the quality of NGS HLA typing data from the 34 participating IHIW laboratories. Completion of the PT program with a minimum score of 95% concordance at the HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 loci satisfied the requirements to submit NGS HLA typing data for the 17th IHIW projects. Together, these PS and PT efforts constituted the 17th IHIW Quality Control project. Overall PT concordance rates for HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DRB3, HLA-DRB4 and HLA-DRB5 were 98.1%, 97.0% and 98.1%, 99.0%, 98.6%, 98.8%, 97.6%, 96.0%, 99.1%, 90.0% and 91.7%, respectively. Across all loci, the majority of the discordance was due to allele dropout. The high cost of NGS HLA genotyping per experiment likely prevented the retyping of initially failed HLA loci. Despite the high HLA genotype concordance rates of the software, there remains room for improvement in the assembly of more accurate consensus DNA sequences by NGS HLA genotyping software.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Prueba de Histocompatibilidad / Secuenciación de Nucleótidos de Alto Rendimiento / Genotipo / Antígenos HLA / Inmunogenética Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Hum Immunol Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Prueba de Histocompatibilidad / Secuenciación de Nucleótidos de Alto Rendimiento / Genotipo / Antígenos HLA / Inmunogenética Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Hum Immunol Año: 2019 Tipo del documento: Article